Carlos Torrado, Clinical Fellow at MD Anderson Cancer Center, recently shared a post by NCI CTEP Clinical Research on X, adding:
“Excited to present our poster tomorrow at the ASCO meeting in collaboration with NCI CTEP!”
Quoting NCI CTEP Clinical Research’s post:
“ASCO24 abstract for ongoing ETCTN (10449).
Phase 1 study of BET inhibitor ZEN003694 in combination with MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer”
Read further
Sources: Carlos Torrado/X and NCI CTEP Clinical Research/X